LDL cholesterol response and statin adherence among high-risk patients initiating treatment. 2016

Suma Vupputuri, and Peter J Joski, and Ryan Kilpatrick, and J Michael Woolley, and Brandi E Robinson, and Michael E Farkouh, and Huifeng Yun, and Monika M Safford, and Paul Muntner
Kaiser Permanente Mid-Atlantic States, Mid-Atlantic Permanente Research Institute, 2101 East Jefferson St, 4W, Rockville, MD 20852. E-mail: Suma.Vupputuri@kp.org.

OBJECTIVE The 2013 American College of Cardiology (ACC)/American Heart Association (AHA) cholesterol treatment guideline recommends monitoring percent reduction in low-density lipoprotein cholesterol (LDL-C) among patients initiating statins as an indication of response and adherence. We examined LDL-C reduction and statin adherence among high-risk patients initiating statins in a real-world setting. METHODS Retrospective cohort study. METHODS The study population included Kaiser Permanente Georgia members (n = 1066) with a history of coronary heart disease or risk equivalent(s) initiating statins in 2011. Percent change in LDL-C was defined using measurements before and 60 to 450 days after statin initiation. Statin adherence was defined by proportion of days covered, categorized as high (≥80%), intermediate (50%-79%), and low (< 50%). RESULTS Overall, 58.4% of patients failed to achieve a ≥ 30% LDL-C reduction after statin initiation. The prevalences of high, intermediate, and low statin adherence were 41.3%, 23.2%, and 35.6%, respectively. Of patients with high adherence, 42.3% did not achieve a ≥ 30% reduction in LDL-C compared with 54.7% and 79.7% of those with intermediate and low statin adherence, respectively. After multivariable adjustment, and compared with those with high adherence, the risk ratios for not achieving a ≥ 30% LDL-C reduction were 1.31 (95% CI, 1.13-1.52) and 1.88 (95% CI, 1.67-2.11), for those with intermediate and low adherence. Women and African Americans were less likely to have high adherence, whereas having cardiologist visits was associated with high adherence. CONCLUSIONS In a real-world setting, many patients did not achieve a 30% or larger LDL-C reduction. These data support the ACC/AHA recommendation to monitor LDL-C response among patients initiating statins.

UI MeSH Term Description Entries
D008078 Cholesterol, LDL Cholesterol which is contained in or bound to low density lipoproteins (LDL), including CHOLESTEROL ESTERS and free cholesterol. LDL Cholesterol,Cholesteryl Linoleate, LDL,LDL Cholesteryl Linoleate,Low Density Lipoprotein Cholesterol,beta-Lipoprotein Cholesterol,Cholesterol, beta-Lipoprotein,beta Lipoprotein Cholesterol
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D008991 Monitoring, Physiologic The continuous measurement of physiological processes, blood pressure, heart rate, renal output, reflexes, respiration, etc., in a patient or experimental animal; includes pharmacologic monitoring, the measurement of administered drugs or their metabolites in the blood, tissues, or urine. Patient Monitoring,Monitoring, Physiological,Physiologic Monitoring,Monitoring, Patient,Physiological Monitoring
D010349 Patient Compliance Voluntary cooperation of the patient in following a prescribed regimen. Client Adherence,Client Compliance,Non-Adherent Patient,Patient Adherence,Patient Cooperation,Patient Noncompliance,Patient Non-Adherence,Patient Non-Compliance,Patient Nonadherence,Therapeutic Compliance,Treatment Compliance,Adherence, Client,Adherence, Patient,Client Compliances,Compliance, Client,Compliance, Patient,Compliance, Therapeutic,Compliance, Treatment,Cooperation, Patient,Non Adherent Patient,Non-Adherence, Patient,Non-Adherent Patients,Non-Compliance, Patient,Nonadherence, Patient,Noncompliance, Patient,Patient Non Adherence,Patient Non Compliance,Patient, Non-Adherent,Therapeutic Compliances,Treatment Compliances
D003327 Coronary Disease An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels. Coronary Heart Disease,Coronary Diseases,Coronary Heart Diseases,Disease, Coronary,Disease, Coronary Heart,Diseases, Coronary,Diseases, Coronary Heart,Heart Disease, Coronary,Heart Diseases, Coronary
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

Suma Vupputuri, and Peter J Joski, and Ryan Kilpatrick, and J Michael Woolley, and Brandi E Robinson, and Michael E Farkouh, and Huifeng Yun, and Monika M Safford, and Paul Muntner
June 2016, International journal of clinical practice,
Suma Vupputuri, and Peter J Joski, and Ryan Kilpatrick, and J Michael Woolley, and Brandi E Robinson, and Michael E Farkouh, and Huifeng Yun, and Monika M Safford, and Paul Muntner
May 2015, European journal of internal medicine,
Suma Vupputuri, and Peter J Joski, and Ryan Kilpatrick, and J Michael Woolley, and Brandi E Robinson, and Michael E Farkouh, and Huifeng Yun, and Monika M Safford, and Paul Muntner
March 2018, Circulation journal : official journal of the Japanese Circulation Society,
Suma Vupputuri, and Peter J Joski, and Ryan Kilpatrick, and J Michael Woolley, and Brandi E Robinson, and Michael E Farkouh, and Huifeng Yun, and Monika M Safford, and Paul Muntner
January 2019, Patient preference and adherence,
Suma Vupputuri, and Peter J Joski, and Ryan Kilpatrick, and J Michael Woolley, and Brandi E Robinson, and Michael E Farkouh, and Huifeng Yun, and Monika M Safford, and Paul Muntner
May 2017, The Malaysian journal of medical sciences : MJMS,
Suma Vupputuri, and Peter J Joski, and Ryan Kilpatrick, and J Michael Woolley, and Brandi E Robinson, and Michael E Farkouh, and Huifeng Yun, and Monika M Safford, and Paul Muntner
April 2011, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology,
Suma Vupputuri, and Peter J Joski, and Ryan Kilpatrick, and J Michael Woolley, and Brandi E Robinson, and Michael E Farkouh, and Huifeng Yun, and Monika M Safford, and Paul Muntner
August 2018, The Journal of clinical endocrinology and metabolism,
Suma Vupputuri, and Peter J Joski, and Ryan Kilpatrick, and J Michael Woolley, and Brandi E Robinson, and Michael E Farkouh, and Huifeng Yun, and Monika M Safford, and Paul Muntner
March 2005, Diabetes care,
Suma Vupputuri, and Peter J Joski, and Ryan Kilpatrick, and J Michael Woolley, and Brandi E Robinson, and Michael E Farkouh, and Huifeng Yun, and Monika M Safford, and Paul Muntner
January 2024, Scientific reports,
Suma Vupputuri, and Peter J Joski, and Ryan Kilpatrick, and J Michael Woolley, and Brandi E Robinson, and Michael E Farkouh, and Huifeng Yun, and Monika M Safford, and Paul Muntner
October 2018, International journal of cardiology,
Copied contents to your clipboard!